AstraZeneca and Oxford University have started developing a version of their coronavirus shot that targets omicron, as researchers study the efficacy of existing vaccines against the latest ...

A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the rapidly-spreading Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an ...

The drive to develop a nasal spray against COVID-19 infection suffered a setback Tuesday after AstraZeneca and Oxford University said a trial produced disappointing results.

Under the new agreement, manufacturing of vaccines at Oxford Biomedica's 84,000 sq. ft manufacturing facility, Oxbox, will be available to AstraZeneca on an as needed basis beyond 2022.

Britain's Oxford Biomedica said on Friday it had signed a new three-year agreement to potentially make AstraZeneca's COVID-19 vaccine beyond 2022, but no volumes were defined in an indication of ...

Background to the agreement with AstraZeneca Oxford Biomedica announced an 18 month supply agreement in September 2020 under a three year Master Supply and Development Agreement (“the Agreement ...

AstraZeneca maintains that the causal mechanism behind TTS is not fully understood and it can occur independently of its vaccine. Meanwhile, lawyers argue that the AstraZeneca-Oxford vaccine is ...

AstraZeneca Plc said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant ...

The vaccine — called Vaxzevria and developed in partnership with the University of Oxford — has been one of the main Covid-19 vaccines worldwide, with more than 3 billion doses supplied since ...

LONDON (AP) — AstraZeneca said Monday that late-stage trials showed that its COVID-19 vaccine with Oxford University was up to 90% effective in preventing disease. The results are based on ...

Britain's Oxford Biomedica announced an agreement to potentially make AstraZeneca's COVID-19 vaccine beyond 2022. It has already manufactured more than 100 million doses since 2020.